Zobrazeno 1 - 10
of 34
pro vyhledávání: '"James P. Allison"'
Autor:
James P. Allison, Cheryl Selinsky, Nicholas L. Bayless, Jill O'Donnell-Tormey, Ute Dugan, Apostolia Maria Tsimberidou, Padmanee Sharma, F. Stephen Hodi, Marko Spasic, Michael Tezlaff, Shivaani Kummar, Leo Nissola, Alexandra Drakaki, David Y. Oh, Lacey J. Kitch, Jennifer C Ayran, Christopher R. Cabanski, Vanessa M. Hubbard-Lucey, Theresa LaVallee, Danny N. Khalil
Publikováno v:
Journal of Clinical Oncology. 39:2573-2573
2573 Background: Immune checkpoint inhibitors (ICIs) have demonstrated durable clinical responses and improved survival in patients (pts) across numerous indications. Despite this progress, the benefit of ICIs is limited to a minority of overall meta
Autor:
Christopher Nguyen, Lawrence Fong, Jaqueline Marquez, Sharon Ng, Matthew H. Spitzer, Meenal Sinha, Alexander Cheung, Rahul Aggarwal, Eric J. Small, Sumit K. Subudhi, Brandon Chen, E Liu, Terence W. Friedlander, Li Zhang, James P. Allison, Kathryn Allaire, Padmanee Sharma
Publikováno v:
Journal of Clinical Oncology. 39:5045-5045
5045 Background: SipT is an FDA-approved autologous cellular immunotherapy targeting Prostatic Acid Phosphatase (PAP) that improves survival in patients with mCRPC. Combining immunotherapies could provide opportunities to enhance efficacy. We perform
Autor:
Baoxiang Guan, Jorge M Blando, Abdel Saci, Shalini Singh, Sreyashi Basu, Seanu Meena Natarajan, Liangwen Xiong, Swetha Anandhan, James P. Allison, Sangeeta Goswami, Padmanee Sharma, Yulong Chen, Matthew D. Galsky, Péter Szabó, Jan Zhang, Wenbin Liu
Publikováno v:
Journal of Clinical Oncology. 39:488-488
488 Background: Immune checkpoint therapy can produce durable anti-tumor responses in metastatic urothelial carcinoma (mUCC); however, the responses are not universal. Despite multiple approvals of immune checkpoint therapy in mUCC, we lack predictiv
Autor:
James P. Allison, Yehia I. Mohamed, Padmanee Sharma, Lina Altameemi, Sunyoung S. Lee, Shalini Singh, Hop S. Tran Cao, Robert A. Wolff, Aliya Qayyum, Kanwal Pratap Singh Raghav, Asif Rashid, James C. Yao, Ahmed Kaseb, Kaseb's, Kristen Carter, Jean Nicolas Vauthey, Luis M Vence, Yun Shin Chun, Jorge Blando, Ching Wei D. Tzeng
Publikováno v:
Journal of Clinical Oncology. 38:4599-4599
4599 Background: In resectable hepatocellular carcinoma (HCC) surgical resection is associated with high recurrence rates. However, there is no approved neoadjuvant or adjuvant therapies yet. Neoadjuvant immunotherapy effect has never been reported i
Autor:
Yehia I. Abugabal, Asif Rashid, Divya Sakamuri, James C. Yao, Ching Wei D. Tzeng, James P. Allison, Shalini Singh, Dan G. Duda, Padmanee Sharma, Manal M. Hassan, Hop S. Tran Cao, Jorge Blando, Hesham M. Amin, Roberto Carmagnani Pestana, Aliya Qayyum, Jean Nicolas Vauthey, Ahmed Kaseb, Robert A. Wolff, Luis M Vence, Yun Shin Chun
Publikováno v:
Journal of Clinical Oncology. 38:486-486
486 Background: In HCC, surgical resection is associated with high recurrence rates, and no effective neoadjuvant or adjuvant therapies currently exist. Immunotherapy using anti-PD-1 antibodies has shown promised but limited increase in survival in a
Autor:
Pavlos Msaouel, Amishi Yogesh Shah, James P. Allison, Luis M Vence, Charles C. Guo, Hao Zhao, Shalini Singh, Neema Navai, Arlene O. Siefker-Radtke, Padmanee Sharma, Fei Duan, John C. Araujo, Colin P.N. Dinney, Rebecca S. S. Tidwell, Jorge Blando, Matthew T. Campbell, Surena F. Matin, Sreyashi Basu, Jianjun Gao, Ashish M. Kamat
Publikováno v:
Journal of Clinical Oncology. 37:4551-4551
4551 Background: In MIBC pts, especially in those with high risk features including lymphovascular invasion, hydronephrosis, T3b disease, or variant histology, cisplatin-based NAC followed by cystectomy improves overall survival as compared with cyst
Autor:
Scott Kopetz, Filip Janku, Gregory Lizée, Michael J. Overman, David G. Menter, Riham Katkhuda, James P. Allison, Kanwal Pratap Singh Raghav, Maliha Nusrat, Van K. Morris, Jason Roszik, Padmanee Sharma, Dipen M. Maru, Jorge Blando
Publikováno v:
Journal of Clinical Oncology. 37:3604-3604
3604 Background: PI3K pathway alterations, PIK3CA mut or PTEN loss, are known to modulate anti-tumor immune microenvironment. MSS CRC pts respond infrequently to immunotherapy, suggesting the presence of a rare MSS immunogenic subset. We investigated
Autor:
Shu-Yun Zhang, Niranjan Yanamandra, Yufeng Li, James F. Smothers, Axel Hoos, Hua-Xin Gao, Christopher Matheny, Heidi Emerich, Christopher B. Hopson, Padmanee Sharma, Wei Wang, Roopa Srinivasan, Paul Bojczuk, Tihui Fu, Hong Shi, James P. Allison, Sabyasachi Bhattacharya
Publikováno v:
Journal of Clinical Oncology. 36:12055-12055
12055Background: GSK1795091 (aka, GSK’091) is a synthetic glycolipid toll-like receptor 4 (TLR4) agonist. TLR4 is a Pattern Recognition Receptor for host defense against bacterial infection, expres...
Autor:
Sherise D. Ferguson, Jacob Mandel, Padmanee Sharma, Jason T. Huse, James P. Allison, Shiao-Pei Weathers, Kathy Hunter, Barbara O’Brien, Gregory N. Fuller, Sujit S. Prabhu, Amy B. Heimberger, Jeffrey S. Weinberg, Kristin Alfaro-Munoz, Marta Penas-Prado, Ying Yuan, John de Groot, Shouhao Zhou, Ganesh Rao, Luis M Vence
Publikováno v:
Journal of Clinical Oncology. 36:2008-2008
2008Background: A Phase III study failed to demonstrate a therapeutic benefit of anti-PD-1 therapy in recurrent GBM. This study was initiated to ascertain tumor immune modulatory properties of pemb...
Autor:
Elias Jabbour, Steven M. Kornblau, Marina Konopleva, Carlos E. Bueso-Ramos, Naval Daver, Juliana E. Hidalgo Lopez, Michael Andreeff, Jing Ning, Padmanee Sharma, Patrick Williams, Jorge Blando, Guillermo Garcia-Manero, Gheath Alatrash, James P. Allison, Hagop M. Kantarjian, Lianchun Xiao, Jorge E. Cortes, Sreyashi Basu, Farhad Ravandi, Zainab Al-Hamal
Publikováno v:
Journal of Clinical Oncology. 36:7016-7016
7016Background: Better defining the immune checkpoint landscape of Acute Myeloid Leukemia will facilitate the rational selection of immune checkpoint targets and combination approaches for future c...